Significant increase in cord blood (CB) vs peripheral blood (PB) alloantigen specific T-regulatory (T-Reg) (CD4+/CD25+/CTLA4+) cells following antigen presenting cell (APC) induction: Molecular, functional and immunophenotypic characterization  by Cairo, M.S. et al.
tissue (membrane/pseudomembrane) may improve the rate of ep-
ithelial healing and decrease cicatricial scarring from ocular
GVHD.
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ELEVATED TNF RECEPTOR LEVELS EARLY AFTER MYELOABLATIVE
BMT PREDICT FOR GVHD AND DEATH
Levine, J.E., Yanik, G.A., Cooke, K.R., Reddy, P., Hutchinson, R.,
Krijanovski, O., McMahon, C., Whitﬁeld, J., Ferrara, J.L. University
of Michigan Cancer Center, Ann Arbor, MI.
Inﬂammatory cytokines are thought to play a signiﬁcant role in
the toxicity of allogeneic BMT. We examined the correlation of
plasma levels of TNF-
 and outcomes in 64 patients receiving
myeloablative allogeneic BMT using soluble TNF-
 receptor 1
(TNFR1) as a surrogate marker for TNF-
. Because baseline
values of TNFR1 pre-BMT ranged ﬁfty-fold between patients
(105-5876 pg/ml), all TNFR1 values post BMT were normalized
to pre-BMT baseline. We ﬁrst evaluated the relationship between
TNFR1 and GVHD. Of the 64 subjects, 36 (56%) subjects had no
GVHD and 28 (44%) had GVHD as their only serious post-
transplant complication (mean day of onset, 28 d). On day 7, when
no subject had GVHD, the mean TNFR1 ratio in subjects who
remained GVHD-free was 2.2 compared to 4.6 in those who
eventually developed GVHD (P  .003). Subjects were divided
equally into low, medium and high categories of day 7 TNFR1
ratios and had rates of eventual GVHD of 27%, 33%, and 62%,
respectively (P  .02). Seven subjects died before day 100, all from
GVHD. Day 28 TNFR1 ratios (the mean day of onset of GVHD)
correlated with mortality by day 100. The mean TNFR1 ratio on
day 28 in subjects who survived to day 100 was 3.0 compared to a
mean ratio of 10.4 in subjects who died before day 100 (P  .001).
Subjects were divided equally into low, medium and high catego-
ries of day 28 TNFR1 ratios and had rates of death by day 100 of
0%, 20%, and 29%, respectively (P  .04). Of the 28 patients who
developed acute GVHD and required treatment of the disease, 14
(50%) responded completely to high-dose steroids and 14 had
incomplete responses. In patients with complete responses TNFR1
ratios decreased, and 8 weeks later were equivalent to ratios in
patients never experiencing GVHD. By contrast, patients who did
not completely respond to high-dose steroids showed increasingly
elevated TNFR1 ratios that were signiﬁcantly different at 8 weeks
post-onset (P  .03). We conclude that post-myeloablative trans-
plant TNFR1 ratios correlate with the subsequent development of
GVHD and day 100 mortality. Subjects who develop GVHD who
respond to treatment show falling TNFR1 levels while non-re-
sponders show increasing levels. We have expanded this prelimi-
nary study to an additional 150 patients with results pending.
Further exploration of the predictive value of post-transplant
TNFR1 ratios may help develop a diagnostic test predictive of
complications days to weeks in advance of their clinical presenta-
tion.
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CYCLOSPORIN A AND MINI SHORT-TERM METHOTREXATE VERSUS
CYCLOSPORIN A AS GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN
PATIENTS WITH BETA THALASSEMIA MAJOR UNDERGOING ALLOGE-
NEIC BLOOD AND MARROW TRANSPLANTATION
Iravani, M., Mousavi, A., Gholibeikian, S., Bahar, B., Samiee, S.,
Ashouri, A., Eghbal, L., Ghavamzadeh, A. Hematology-Oncology &
Bone Marrow Transplantation Research Center, Tehran University of
Medical Sciences, Tehran, Islamic Republic of Iran.
In this study, we compared the effects of cyclosporine A (CsA)
alone as graft-versus-host disease (GVHD) prophylaxis versus cy-
closporine with short course methotrexate (MTX) in patients with
thalassemia who received hematopoietic stem cell transplantation
from HLA-identical siblings. One hundred forty patients were
enrolled in this study. The ﬁrst group, 50 patients (class I and II),
received CsA alone 3 mg/kg IV from day 2 to 5 followed by
12.5 mg/kg p.o. which was tapered according to the patient’s
condition. The other group of 90 (class I, II, III) patients received
the combination of CsA  MTX in which CsA was used with the
above mentioned dose and MTX was 10 mg/m2 on day 1 and 6
mg/m2 on days3 and6. Incidence of acute GVHD grade II-IV
in the CsA group was 78% and in the CsA  MTX group was
52.2%, which was statistically signiﬁcant (P  .001).There was no
signiﬁcant difference in the incidence of chronic GVHD between
two groups. The mean time to neutrophil engraftment to 0.5 
109/L was 14 and 23 days for CsA group and CsA  MTX group,
respectively (P  .001). There were no signiﬁcant differences for
platelet recovery between the two groups. Graft failure in the CsA
and CsAMTX groups was seven (14%) and nine (10%) patients,
respectively (P  .58). The 5 year overall survival (OS) and disease
free survival (DFS) was 77% and 58% in the CsA group versus
85% and 80% in the CsA MTX group, respectively. OS had no
statistically signiﬁcant differences between two groups (P  .56)
but there were signiﬁcant differences for DFS between the two
groups (P  .05). This study shows that the CsA and short term
MTX for a GVHD prophylaxis regimen can reduce the incidence
of aGVHD grade II to IV and improve the probability for survival
in patients with thalassemia major given allogeneic blood and
marrow transplantation.
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SIGNIFICANT INCREASE IN CORD BLOOD (CB) VS PERIPHERAL BLOOD
(PB) ALLOANTIGEN SPECIFIC T-REGULATORY (T-Reg) (CD4/CD25/
CTLA4) CELLS FOLLOWING ANTIGEN PRESENTING CELL (APC) IN-
DUCTION: MOLECULAR, FUNCTIONAL AND IMMUNOPHENOTYPIC
CHARACTERIZATION
Cairo, M.S., Satwani, P., Oberﬁeld, N., Vlad, G., Simpson, L.,
van de Ven, C., Chang, C. Columbia University, New York, NY.
We have demonstrated that HLA disparate (2-3 antigen) CB can
successfully be used as an alternative allogeneic (allo) cell source
and more importantly, is associated with decreased severe acute
and chronic GVHD (Cairo et al., Blood, 1997). Studies from our lab
have suggested an immaturity in CB T cell immunity in part
secondary to decreased IL-12, IL-15 and IL-18 gene expression
and protein production. However, CB T reg cells may also actively
and speciﬁcally suppress unwanted allo immune responses. In this
study we compared the functional and molecular events with the
induction of allo speciﬁc CB vs PB T-reg cells. Brieﬂy, Mutz-3
immature dendritic cells (iDC) and monocyte derived (GM-CSF/
IL-4  7 d) (m)DC were utilized for APC in vitro stimulation.
CD4, CD4/CD25 and CD4/CD25 CB and PB were puri-
ﬁed by CD4 and CD25 selection (Miltenyi, Auburn, CA). CD4/
25 proliferation was determined by in vitro priming with iDC or
mDC 1:5 ratio with 3H-thymidine in both primary and secondary
MLR reactions. T-reg suppression was measured with CD4/25/
CD4/25 iDC at a 1:1:0.1 ratio. RT-PCR was used to measure
gene expression of GITR, FoxP-3, CTLA-4, CD25, GAPDH and
ﬂow cytometry for GITR, CTLA-4, CD25 and IL-10 expression.
Naive PB CD4/25 (T-reg) signiﬁcantly suppressed CD4/
CD25 proliferation compared to CB T-reg (60% vs 10%, P 
.02). However, in the secondary MLR response CB vs PB CD4
proliferation was signiﬁcantly less with Mutz-iDC (10.5  3.3 vs
48.5  13.1  105 cpm, P  .02) suggesting a decrease in allo
response of CB vs PB CD4 T cells. Naive CB vs PB CD4/25
T-reg had similar gene expression of GITR, FoxP-3, CTLA-4 and
CD25. However, GITR protein expression was signiﬁcantly
higher in CB vs PB (11  3 vs 3.4  1.6%, P  .05). Following
Mutz-iDC induction of CD4/25, T-reg cells demonstrated sim-
ilar gene expression of CTLA-4, GITR, FoxP-3 and CD25 (3-8
fold) with CB vs PB, however, there was a signiﬁcant increase in
CB vs PB protein expression of CD25 (50  1 vs 35  2%, P 
.02) and CTLA-4 (25.2  5.5 vs 12.5  0.9%, P  .05). Further-
more, CB T-reg suppressive activity was allo-antigen speciﬁc
(Mutz-iDC vs MHC I mismatched allo-mDC: 31.5  4 vs 73 
10.5%, P  .001) and IL-10 independent. In summary, there is a
signiﬁcant increase in allogeneic speciﬁc APC induction of CB vs
PB CD25/CTLA-4/CD4 T-reg cells which may in part be
responsible for the suppression and decrease in alloantigen recog-
nition and immune response of CB CD4/CD25 T cells.
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